Enling Chang and IBBME UofT

When:
February 13, 2020 @ 12:30 pm – 1:00 pm
2020-02-13T12:30:00-05:00
2020-02-13T13:00:00-05:00
Where:
Red Seminar Room
Donnelly Building

Event Name: Graduate Seminar Series: Cell and Tissue Stream

Graduate Seminar Series for the Institute of Biomaterials and Biomedical Engineering (IBBME). This day is for cell and tissue stream presenters.

Location: Red Seminar Room – Donnelly Building

Presentation Title: Combination of photodynamic therapy and chemotherapy for cancer treatment by using paclitaxel loaded porphyrin-shelled nanoemulsions
Abstract: To improve the efficacy of single therapy, we have created paclitaxel (PTX) loaded porphyrin-shelled nanoemulsions (PTX-NewPS) for combined therapy of porphyrin photodynamic therapy (PDT) and chemotherapy by PTX. NewPS is created by the self-assembly of porphyrin salt around an oil core to have a stable porphyrin-shelled oil-in-water nanoplatform. The oil core of droplet enabled efficient encapsulation of hydrophobic PTX, which is recognized as an efficient chemotherapy drugs associated with severe side effects. The PTX-NewPS with a high-density porphyrin on shell and good PTX loading in oil core will facilitate our investigation of combination therapy by PDT and chemotherapy. Meanwhile, PTX-NewPS show unique optical ability including producing a narrow, red-shifted (from 671nm to 715nm) Q-band with increased absorbance for photoacoustic imaging (at 715nm), and activatable porphyrin monomer’ fluorescence at 671 nm upon nanostructure uptake and eventual dissociation in cancer cells, which potentiate optical imaging for tracking drug delivery and imaging –guided treatment. A library of PTX-NewPSs are designed and synthesized to optimize the formulation for excellent drug loading, prolonged blood circulation, and optimal porphyrin/drug ratio of combination therapy. In vitro and in vivo studies are planned and performed to investigate whether the combination of chemotherapy and PDT can promote stronger anti-tumor ability compared to each single therapy. A combination Index (CI) that introduced by Chou T.C. and Talalay P. will be used for quantitative estimation of the interaction of combination therapy. We anticipate to reach the goals of enhancing the therapeutic effect and reducing the side effects using the optimized PTX-NewPS. In summary, a combining chemotherapy plus PDT with PTX-NewPS system would be developed as a novel and synergistic tumor killing tool for overcoming the limitations of PDT alone or chemotherapy alone in tumor treatment in this study.
Supervisor Name: Gang Zheng
Year of Study: 2
Program of Study: MASc

Powered by Calendly.com